$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr

$capr Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-K Financial Statement

#000114420417014866 Filed on March 16, 2017

Income Statement

Concept	2017 Q1	2015 Q4	2015
Revenue	$0.00	$1.120M	$5.518M
YoY Change	-100.0%	-20.0%	15.27%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.190M	$1.080M	$4.370M
YoY Change	10.19%	58.82%	44.7%
% of Gross Profit
Research & Development	$3.260M	$3.330M	$13.76M
YoY Change	-24.9%	29.07%	76.66%
% of Gross Profit
Depreciation & Amortization	$38.77K	$30.00K	$110.9K
YoY Change	22.68%	200.0%	164.62%
% of Gross Profit
Operating Expenses	$4.450M	$4.410M	$18.13M
YoY Change	-17.98%	34.86%	67.79%
Operating Profit			-$12.61M
YoY Change			109.57%
Interest Expense	-$100.0K	-$60.00K	$248.6K
YoY Change	-251.23%	0.0%	24.0%
% of Operating Profit
Other Income/Expense, Net			-$245.5K
YoY Change			23.62%
Pretax Income	-$3.670M	-$3.350M	-$12.86M
YoY Change	-14.05%	73.58%	106.75%
Income Tax
% Of Pretax Income
Net Earnings	-$3.670M	-$3.350M	-$12.86M
YoY Change	-13.98%	73.58%	106.82%
Net Earnings / Revenue		-299.11%	-233.02%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.715M	-$2.055M	-$8.088M
COMMON SHARES
Basic Shares Outstanding	21.40M shares	16.25M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q1	2015 Q4	2015
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.74M	$13.57M	$13.57M
YoY Change	-17.68%	68.96%	68.99%
Cash & Equivalents	$2.750M	$5.568M	$5.570M
Short-Term Investments	$8.993M	$7.999M	$8.000M
Other Short-Term Assets	$1.530M	$210.0K	$210.0K
YoY Change	378.12%	-93.48%	-93.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$13.46M	$13.99M	$13.99M
YoY Change	-9.6%	20.52%	20.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$410.0K	$318.6K	$320.0K
YoY Change	18.86%	38.84%	39.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$60.00K	$70.00K	$70.00K
YoY Change	-14.29%	16.67%	16.67%
Total Long-Term Assets	$608.0K	$2.080M	$2.080M
YoY Change	-70.98%	2.73%	2.97%
TOTAL ASSETS
Total Short-Term Assets	$13.46M	$13.99M	$13.99M
Total Long-Term Assets	$608.0K	$2.080M	$2.080M
Total Assets	$14.07M	$16.07M	$16.07M
YoY Change	-17.17%	17.88%	17.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.620M	$2.880M	$2.880M
YoY Change	-29.0%	35.21%	35.21%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.299M	$6.529M	$6.530M
YoY Change	-55.06%	3.64%	3.65%
LONG-TERM LIABILITIES
Long-Term Debt	$17.01M	$9.160M	$9.160M
YoY Change	67.42%	0.0%	0.0%
Other Long-Term Liabilities	$950.0K	$1.420M	$1.420M
YoY Change	66.67%	-67.95%	-67.95%
Total Long-Term Liabilities	$17.96M	$10.57M	$10.58M
YoY Change	67.43%	-22.15%	-22.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.299M	$6.529M	$6.530M
Total Long-Term Liabilities	$17.96M	$10.57M	$10.58M
Total Liabilities	$21.26M	$17.10M	$17.10M
YoY Change	17.67%	-13.98%	-13.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$57.65M	-$35.17M
YoY Change	46.17%	57.62%
Common Stock	$50.42M	$34.13M
YoY Change	31.53%	112.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.192M	-$1.032M	-$1.030M
YoY Change
Total Liabilities & Shareholders Equity	$14.07M	$16.07M	$16.07M
YoY Change	-17.17%	17.88%	17.9%

Cashflow Statement

Concept	2017 Q1	2015 Q4	2015
OPERATING ACTIVITIES
Net Income	-$3.670M	-$3.350M	-$12.86M
YoY Change	-13.98%	73.58%	106.82%
Depreciation, Depletion And Amortization	$38.77K	$30.00K	$110.9K
YoY Change	22.68%	200.0%	164.62%
Cash From Operating Activities	-$4.676M	-$3.650M	-$10.82M
YoY Change	11.86%	70.56%	-1227.08%
INVESTING ACTIVITIES
Capital Expenditures	$3.126K	$0.00	$129.7K
YoY Change	-93.18%	-100.0%	-20.28%
Acquisitions
YoY Change
Other Investing Activities	$4.000M	$5.000M	-$7.990M
YoY Change	-27.14%	1415.15%
Cash From Investing Activities	$4.001M	$4.990M	-$8.140M
YoY Change	-26.59%	1248.65%	-5914.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00		$16.45M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	0.000	16.49M
YoY Change	-100.0%		216.51%
NET CHANGE
Cash From Operating Activities	-$4.676M	-3.650M	-10.82M
Cash From Investing Activities	$4.001M	4.990M	-8.140M
Cash From Financing Activities	$0.00	0.000	16.49M
Net Change In Cash	-$675.3K	1.340M	-2.470M
YoY Change	-110.89%	-175.71%	-139.14%
FREE CASH FLOW
Cash From Operating Activities	-$4.676M	-$3.650M	-$10.82M
Capital Expenditures	$3.126K	$0.00	$129.7K
Free Cash Flow	-$4.679M	-$3.650M	-$10.95M
YoY Change	10.72%	67.43%	-1473.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1347225	USD
CY2015Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	211938	USD
CY2015	capr	Collaboration Revenue CollaborationRevenue	3776041	USD
CY2016	us-gaap	Revenue From Grants RevenueFromGrants	808512	USD
CY2016	us-gaap	Revenues Revenues	3998618	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16042082	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4933054	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	20975136	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-16976518	USD
CY2016	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	14407	USD
CY2016	us-gaap	Interest Expense InterestExpense	344665	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1830258	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-18806776	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-5861	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18812637	USD
CY2015Q4	capr	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	13600000	USD
CY2016	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	-8720	USD
CY2015	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	831246	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	110865	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2016Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	223335	USD
CY2016Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	3100000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	125719	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	1573224	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	1962465	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-2977024	USD
CY2016	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	1347225	USD
CY2015	capr	Increase Decrease From Grants Receivable IncreaseDecreaseFromGrantsReceivable	-148295	USD
CY2016	capr	Increase Decrease From Grants Receivable IncreaseDecreaseFromGrantsReceivable	11397	USD
CY2015	capr	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-24920	USD
CY2016	capr	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	132289	USD
CY2015	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	14826	USD
CY2015Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	0	USD
CY2016	capr	Collaboration Revenue CollaborationRevenue	3190106	USD
CY2015	us-gaap	Revenue From Grants RevenueFromGrants	1741607	USD
CY2015	us-gaap	Revenues Revenues	5517648	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13757279	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4372195	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	18129474	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-12611826	USD
CY2015	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	3113	USD
CY2015	us-gaap	Interest Expense InterestExpense	248626	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-245513	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-12857339	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9385	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12847954	USD
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.81
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.01
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15902133	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18551013	shares
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13864817	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13975	USD
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1962465	USD
CY2016	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	508280	USD
CY2015	capr	Increase Decrease In Accounts Payable And Accrued Expenses Related Party IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty	-81378	USD
CY2016	capr	Increase Decrease In Accounts Payable And Accrued Expenses Related Party IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty	136883	USD
CY2015	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	246724	USD
CY2016	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	344106	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3776041	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3190106	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10817286	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15801620	USD
CY2015	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	17989625	USD
CY2016	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	17997361	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	10000000	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	13000000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	129697	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	191970	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-8140852	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5191100	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	16491679	USD
CY2016	us-gaap	Interest Paid InterestPaid	1343	USD
CY2015	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	18628792	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8034765	USD
CY2015	us-gaap	Interest Paid InterestPaid	2685	USD
CY2016	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13864817	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16446218	USD
CY2016	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	1769	USD
CY2015	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	21530	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2363928	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2466459	USD
CY2016	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	13975	USD
CY2015	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	45461	USD
CY2015	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	4750000	USD
CY2016	capr	Increase Decrease In Other Long Term Debt IncreaseDecreaseInOtherLongTermDebt	3100000	USD
CY2015	capr	Increase Decrease In Other Long Term Debt IncreaseDecreaseInOtherLongTermDebt	0	USD
CY2016Q4	capr	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	16200000	USD
CY2016	us-gaap	Depreciation Depreciation	85888	USD
CY2015	us-gaap	Depreciation Depreciation	62116	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	250677	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	173708	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	48749	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	43276	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	43733	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4330	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2165	USD
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6233153	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7690285	shares
CY2016Q4	us-gaap	Marketable Securities MarketableSecurities	12990510	USD
CY2016Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	30000	USD
CY2016Q1	capr	Warrant Redemption Weighted Average Common Stock Per Share Threshold Limit WarrantRedemptionWeightedAverageCommonStockPerShareThresholdLimit	7.50
CY2016Q1	capr	Warrant Redemption Fees Per Share WarrantRedemptionFeesPerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21399019	shares
CY2015	capr	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	15401	shares
CY2015	capr	Class Of Warrant Or Right Exercised Weighted Average Exercise Price ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice	2.27
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	235830	shares
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	303881	shares
CY2015	capr	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	52650	shares
CY2015	capr	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	47.00
CY2016	capr	Class Of Warrant Or Right Granted ClassOfWarrantOrRightGranted	846073	shares
CY2016	capr	Class Of Warrant Or Right Granted Weighted Average Exercise Price ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice	4.50
CY2014Q4	capr	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	10.02
CY2015Q4	capr	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	2.27
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.84
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.09
CY2016Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	17300000	USD
CY2016Q4	capr	Disbursement Amount Under Grant Award DisbursementAmountUnderGrantAward	1100000	USD
CY2015Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	17957	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	670932	USD
CY2016	us-gaap	Payments For Royalties PaymentsForRoyalties	20000	EUR
CY2013Q4	capr	Additional Milestone Payments To Be Received Contingent Upon Exercise Of Options AdditionalMilestonePaymentsToBeReceivedContingentUponExerciseOfOptions	325000000	USD
CY2016	dei	Document Type DocumentType	10-K
CY2016	dei	Amendment Flag AmendmentFlag	false
CY2016	dei	Document Period End Date DocumentPeriodEndDate	2016-12-31
CY2016Q2	dei	Entity Public Float EntityPublicFloat	32566107	USD
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2016	dei	Entity Registrant Name EntityRegistrantName	CAPRICOR THERAPEUTICS, INC.
CY2016	dei	Entity Central Index Key EntityCentralIndexKey	0001133869
CY2016	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2016	dei	Trading Symbol TradingSymbol	CAPR
CY2017Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21399019	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	147429	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	98679	USD
CY2016	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1500000	USD
CY2015	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-6248723	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16446218	USD
CY2015	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1573224	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	45461	USD
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.25in; size: 8.5in 11.0in">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify">The preparation of financial statements in conformity with U.S. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">generally accepted accounting principles (“U.S. GAAP”)</font> requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The most sensitive estimates relate to the period over which collaboration revenue is recognized<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">, recoverability and fair value of intangible assets,</font> and the assumptions used to estimate stock-based compensation expense. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1081903	shares
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1300000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	686013	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	48749	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	492274	USD
CY2016Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	6608382	shares
CY2016Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	1.62
CY2016	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y4M6D
CY2016Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	5187414	shares
CY2016Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	1.05
CY2016	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P5Y8M19D
CY2016Q4	capr	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	4.01
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	3500000	USD
CY2016	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M24D
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	142031	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	131708	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	48749	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2015Q4	us-gaap	Marketable Securities MarketableSecurities	7999010	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	378210	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	292722	USD

Files In Submission

Name	View Source	Status
0001144204-17-014866-index-headers.html	Edgar Link	pending
0001144204-17-014866-index.html	Edgar Link	pending
0001144204-17-014866.txt	Edgar Link	pending
0001144204-17-014866-xbrl.zip	Edgar Link	pending
capr-20161231.xml	Edgar Link	completed
capr-20161231.xsd	Edgar Link	pending
capr-20161231_cal.xml	Edgar Link	unprocessable
capr-20161231_def.xml	Edgar Link	unprocessable
capr-20161231_lab.xml	Edgar Link	unprocessable
capr-20161231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v461171_10k.htm	Edgar Link	pending
v461171_ex21-1.htm	Edgar Link	pending
v461171_ex23-1.htm	Edgar Link	pending
v461171_ex31-1.htm	Edgar Link	pending
v461171_ex31-2.htm	Edgar Link	pending
v461171_ex32-1.htm	Edgar Link	pending
v461171_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr

2017 Q1 Form 10-K Financial Statement

#000114420417014866 Filed on March 16, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CAPR CAPRICOR THERAPEUTICS, INC. Stock $capr

2017 Q1 Form 10-K Financial Statement

#000114420417014866 Filed on March 16, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr